Clostridium difficile in 7 European countries and North America: Fidaxomicin vs vancomycin therapy  by Crook, D. et al.
e l of In
T
F
S
D
T
R
C
F
D
W
1
2
3
4
5
S
6
7
c
c
ﬁ
E
p
d
T
a
S
t
r
p
7
F
C
(
f
o
o
8
v
r
t
(
J
l
(
o
s
t
s
n
h242 15th ICID Abstracts / International Journa
ype: Poster Presentation
inal Abstract Number: 45.074
ession: Bacterial Infections
ate: Friday, June 15, 2012
ime: 12:45-14:15
oom: Poster & Exhibition Area
lostridiumdifﬁcile in 7 European countries and North America:
idaxomicin vs vancomycin therapy
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Background: Clostridium difﬁcile infection (CDI) is the primary
ause of antibiotic-associated diarrhoea. This phase 3 randomised,
ontrolled trial was designed to compare efﬁcacy and safety of
daxomicin with vancomycin in patients with conﬁrmed CDI in
urope (E) and North America (NA).
Methods: Eligible patients were adults with acute, toxin-
ositive CDI. Patients received oral ﬁdaxomicin (200mg twice
aily) or oral vancomycin (125mg 4 times daily) for 10 days.
he primary endpoint was clinical cure (resolution of diarrhoea
nd no further need for CDI therapy; noninferiority margin -10%).
econdary endpoints were CDI recurrence within 4 weeks after
reatment and sustained response (clinical cure with no recur-
ence). Analysis was done in the modiﬁed intention-to-treat and
er protocol populations.
Results: The mITT population included 509 CDI patients from
European countries (UK-53, Belgium-42, Germany-37, Italy-27,
rance-19, Sweden-11, Spain-9), the US (150) and Canada (161).
DI patients tended to be older in E (median age 67 yrs) than in NA
61 yrs; p<.05), weremore likely to receive concomitant antibiotics
or other infections in E (35%) than in NA (27%; p<.05), were more
ften treated as inpatients (84% in E vs 58% in NA; p<.05). Fidax-
micin was non-inferior to vancomycin for clinical cure (mITT:
7.7% vs 86.8%; difference .9, lower 97.5% CL, -4.9) and superior to
ancomycin for recurrence (12.7% vs 26.9%, p<.001) and sustained
esponse (76.6% vs 63.4%, p=.001). InNA, 46%of isolates belonged to
he BI group (also known as NAP1 and 027), followed by Y (10%), G
7%), and J (4%). In Europe, the most prevalent strains were Y (16%),
(15%), BI (10%), G (8%), and BK (7%). Susceptibilities were simi-
ar in E and NA to ﬁdaxomicin (MIC90=0.25g/mL), vancomycin
MIC90=0.5g/mL), and metronidazole (MIC90=1g/mL).
Conclusion: Initial response to treatment was similar for ﬁdax-
micin and vancomycin, but the incidence of recurrence was
igniﬁcantly lower in ﬁdaxomicin-treated subjects. Outcomes of
reatment were similar in Europe and North America although
mall differences in patient characteristics and responses were
oted.
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Carriage of healthcare-associated methicillin-resistant Staphy-
lococcus aureus and empiric treatment for skin and soft tissue
infections
I. Uc¸kay ∗, A. Reber, N. Dunkel, A. Moldovan, D. Lew
University Hospital of Geneva, Geneva, Switzerland
Background: Previous skin carriage of healthcare-associated
methicillin-resistant Staphylococcus aureus (HA-MRSA) leads fre-
quently to empiric MRSA coverage for the antibiotic treatment of
skin and soft tissue infections.
Methods: Retrospective cohort study between January 1996
and -June 2010 including adult orthopedic patients hospitalized
at Geneva University Hospitals (MRSA prevalence; 30%).
Results: A total of 378 skin and soft tissue infections in 346
patientswere retrieved.Amongall episodes, 102 revealedapositive
currentMRSA status (during 2weeks preceding infection; 102/378;
27%) and 70 (19%) were MRSA carriers in the past. The sensitivity,
speciﬁcity, positive and negative predictive values of currentMRSA
skin carriage topredict abscesses due toMRSAwere0.68, 0.77, 0.19,
and 0.97, respectively. Fifty-four current MRSA carriers (54/102,
53%) and 30 past carriers (43%) were successfully treated with a
non-MRSA antibiotic agent. In multivariate Cox regression analy-
sis, anti-MRSA antibiotic coverage (hazard ratio 1.2, 95% CI 0.5-2.8)
and duration of antibiotic therapy (HR 1.0, 95% CI 0.96-1.02) did not
inﬂuence treatment failure amongpatientswithpositiveMRSAcar-
riage, in contrast to presence of immune suppression (HR 7.8, 95%
CI 1.8-34.1).
Conclusion: Current or past HA-MRSA skin carriage poorly
predicts the need for anti-MRSA coverage for the antibiotic treat-
ment of skin and soft tissue infections in hospitalized orthopaedic
patients.
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Characterisation, detection of Metallo -lactamases and Amp C
in Pseudomonas aeruginosa in a tertiary care hospital
A.R. Ugargol
St John’s medical college, Bangalore, India
Background: Pseudomonas aeruginosa is a common nosocomial
pathogen.It is a major cause of multidrug resistance infections in
hospitalized patients. Antibiotic resistance and production of vir-
ulence factors increases the morbidity and mortality. This leads to
rising costs of care resulting from prolonged hospital stay and the
need for more expensive drugs.
